<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="17896"><DrugName>NMDA/calcium channel antagonists, Allelix</DrugName><DrugSynonyms><Name><Value>NMDA/calcium channel antagonists, Allelix</Value></Name></DrugSynonyms><CompanyOriginator id="14041">NPS Allelix Corp</CompanyOriginator><CompaniesSecondary><Company id="14041">NPS Allelix Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="14041" type="Company"><TargetEntity id="5000140067" type="organizationId">NPS Allelix Corp</TargetEntity></SourceEntity><SourceEntity id="119" type="ciIndication"><TargetEntity id="G40" type="ICD10"></TargetEntity><TargetEntity id="345" type="ICD9"></TargetEntity><TargetEntity id="10015037" type="MEDDRA"></TargetEntity><TargetEntity id="D004827" type="MeSH"></TargetEntity><TargetEntity id="-2005570698" type="omicsDisease"></TargetEntity><TargetEntity id="115" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"></TargetEntity><TargetEntity id="331.0" type="ICD9"></TargetEntity><TargetEntity id="10012271" type="MEDDRA"></TargetEntity><TargetEntity id="D000544" type="MeSH"></TargetEntity><TargetEntity id="-1268969445" type="omicsDisease"></TargetEntity><TargetEntity id="101" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="170" type="ciIndication"><TargetEntity id="G10" type="ICD10"></TargetEntity><TargetEntity id="10020469" type="MEDDRA"></TargetEntity><TargetEntity id="D006816" type="MeSH"></TargetEntity><TargetEntity id="399" type="ORPHANET"></TargetEntity><TargetEntity id="-682751376" type="omicsDisease"></TargetEntity><TargetEntity id="126" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="233" type="ciIndication"><TargetEntity id="10053643" type="MEDDRA"></TargetEntity><TargetEntity id="D019636" type="MeSH"></TargetEntity><TargetEntity id="-1502359765" type="omicsDisease"></TargetEntity><TargetEntity id="160" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="65" type="ciIndication"><TargetEntity id="D020521" type="MeSH"></TargetEntity><TargetEntity id="-1815339002" type="omicsDisease"></TargetEntity><TargetEntity id="93" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="770" type="ciIndication"><TargetEntity id="10019196" type="MEDDRA"></TargetEntity><TargetEntity id="D006259" type="MeSH"></TargetEntity><TargetEntity id="-774444404" type="omicsDisease"></TargetEntity><TargetEntity id="1187" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="93" type="Action"><TargetEntity id="361" type="Mechanism">Calcium Channel Blockers</TargetEntity></SourceEntity><SourceEntity id="1246" type="Action"><TargetEntity id="2719" type="Mechanism">NMDA Glycine B Receptor Antagonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="119">Epilepsy</Indication><Indication id="14">Alzheimers disease</Indication><Indication id="170">Huntingtons chorea</Indication><Indication id="233">Neurodegenerative disease</Indication><Indication id="65">Stroke</Indication><Indication id="770">Head injury</Indication></IndicationsSecondary><ActionsPrimary><Action id="1246">NMDA glycine antagonist</Action><Action id="93">Calcium channel inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1615">Neuroprotectant</Action><Action id="70">Anticonvulsant agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N3</Code><Name>ANTI-EPILEPTICS</Name></Ephmra><Ephmra><Code>C8</Code><Name>CALCIUM ANTAGONISTS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-28T09:46:37.000Z</LastModificationDate><ChangeDateLast>2006-02-14T11:52:02.000Z</ChangeDateLast><AddedDate>1998-05-20T15:31:56.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;NPS-Allelix (formerly Allelix Biopharmaceuticals) was investigating a series of NMDA/calcium channel antagonists for the potential treatment of neurodegenerative disease. However, no development has been reported since 1997 and research in this area by the company has since been confirmed to have been discontinued [&lt;ulink linkID="375991" linkType="reference"&gt;375991&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In WO-09745115, Allelix lists schizophrenia, dementia, epilepsy, muscle hypertonia, pain, cognitive disorders, motor neurone disease, head injury and cerebrovascular ischemia as possible therapeutic applications for the compounds (representative structure shown) [&lt;ulink linkID="287679" linkType="reference"&gt;287679&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14041">NPS Allelix Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="233">Neurodegenerative disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-07-25T00:00:00.000Z</StatusDate><Source id="375991" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14041">NPS Allelix Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-07-25T00:00:00.000Z</StatusDate><Source id="375991" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14041">NPS Allelix Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-07-25T00:00:00.000Z</StatusDate><Source id="375991" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14041">NPS Allelix Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="770">Head injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-07-25T00:00:00.000Z</StatusDate><Source id="375991" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14041">NPS Allelix Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-07-25T00:00:00.000Z</StatusDate><Source id="375991" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14041">NPS Allelix Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2000-07-25T00:00:00.000Z</StatusDate><Source id="375991" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14041">NPS Allelix Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-05-20T00:00:00.000Z</StatusDate><Source id="287679" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14041">NPS Allelix Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="770">Head injury</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-05-20T15:31:57.000Z</StatusDate><Source id="287679" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14041">NPS Allelix Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="119">Epilepsy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-05-20T15:31:57.000Z</StatusDate><Source id="287679" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14041">NPS Allelix Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="170">Huntingtons chorea</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-05-20T15:31:57.000Z</StatusDate><Source id="287679" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14041">NPS Allelix Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-05-20T15:31:57.000Z</StatusDate><Source id="287679" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14041">NPS Allelix Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="233">Neurodegenerative disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">1998-05-20T15:31:57.000Z</StatusDate><Source id="287679" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00255"><Name>Calcium channel</Name><SwissprotNumbers><Swissprot>P50077</Swissprot><Swissprot>Q25452</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01435"><Name>NMDA receptor</Name><SwissprotNumbers><Swissprot>O60391</Swissprot><Swissprot>Q8TCU5</Swissprot><Swissprot>Q8VHN2</Swissprot><Swissprot>Q91ZU9</Swissprot><Swissprot>Q9R1M7</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CCOC(=O)CNCCC=C(c1ccccc1)c2ccccc2</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>